Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes - PubMed (original) (raw)
Randomized Controlled Trial
. 2015 Nov 26;373(22):2117-28.
doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi; EMPA-REG OUTCOME Investigators
Collaborators, Affiliations
- PMID: 26378978
- DOI: 10.1056/NEJMoa1504720
Free article
Randomized Controlled Trial
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al. N Engl J Med. 2015.
Free article
Abstract
Background: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
Methods: We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina.
Results: A total of 7020 patients were treated (median observation time, 3.1 years). The primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There were no significant between-group differences in the rates of myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization for heart failure (2.7% and 4.1%, respectively; 35% relative risk reduction), and death from any cause (5.7% and 8.3%, respectively; 32% relative risk reduction). There was no significant between-group difference in the key secondary outcome (P=0.08 for superiority). Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events.
Conclusions: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).
Comment in
- Understanding EMPA-REG OUTCOME.
Muskiet MH, van Raalte DH, van Bommel EJ, Smits MM, Tonneijck L. Muskiet MH, et al. Lancet Diabetes Endocrinol. 2015 Dec;3(12):928-9. doi: 10.1016/S2213-8587(15)00424-6. Lancet Diabetes Endocrinol. 2015. PMID: 26590679 No abstract available. - Understanding EMPA-REG OUTCOME.
Ceriello A, Genovese S, Mannucci E, Gronda E. Ceriello A, et al. Lancet Diabetes Endocrinol. 2015 Dec;3(12):929-30. doi: 10.1016/S2213-8587(15)00426-X. Lancet Diabetes Endocrinol. 2015. PMID: 26590680 No abstract available. - Understanding EMPA-REG OUTCOME.
Gilbert RE, Connelly KA. Gilbert RE, et al. Lancet Diabetes Endocrinol. 2015 Dec;3(12):930-1. doi: 10.1016/S2213-8587(15)00427-1. Lancet Diabetes Endocrinol. 2015. PMID: 26590681 No abstract available. - Preventing cardiovascular events with empagliflozin: at what cost?
Naci H, Basu S, Yudkin JS. Naci H, et al. Lancet Diabetes Endocrinol. 2015 Dec;3(12):931. doi: 10.1016/S2213-8587(15)00439-8. Lancet Diabetes Endocrinol. 2015. PMID: 26590682 No abstract available. - Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes.
Ingelfinger JR, Rosen CJ. Ingelfinger JR, et al. N Engl J Med. 2015 Nov 26;373(22):2178-9. doi: 10.1056/NEJMe1512602. N Engl J Med. 2015. PMID: 26605932 No abstract available. - Superiority trials: statistical trickery or mass blindness?
Shafiq N, Malhotra S. Shafiq N, et al. Postgrad Med J. 2016 Feb;92(1084):118-9. doi: 10.1136/postgradmedj-2015-133769. Epub 2015 Nov 30. Postgrad Med J. 2016. PMID: 26621824 No abstract available. - [New therapy option for type 2 diabetes mellitus: EMPA-REG study].
Windler E, Nitschmann S. Windler E, et al. Internist (Berl). 2016 Jan;57(1):102-3. doi: 10.1007/s00108-015-3848-z. Internist (Berl). 2016. PMID: 26634255 German. No abstract available. - [Empagliflozin reduces cardiovascular mortality in diabetic patients with previous cardiovascular events].
Seguí Díaz M. Seguí Díaz M. Semergen. 2016 Jul-Aug;42(5):e38-9. doi: 10.1016/j.semerg.2015.10.010. Epub 2015 Dec 3. Semergen. 2016. PMID: 26671327 Spanish. No abstract available. - ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
Shekelle P. Shekelle P. Ann Intern Med. 2016 Jan 19;164(2):JC2. doi: 10.7326/ACPJC-2016-164-2-002. Ann Intern Med. 2016. PMID: 26784492 No abstract available. - Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Lachin JM, Inzucchi SE. Zinman B, et al. N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981940 No abstract available. - Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Sarafidis PA, Tsapas A. Sarafidis PA, et al. N Engl J Med. 2016 Mar 17;374(11):1092. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981941 No abstract available. - Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Fischereder M, Schönermarck U. Fischereder M, et al. N Engl J Med. 2016 Mar 17;374(11):1092-3. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981942 No abstract available. - Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Edwards JL. Edwards JL. N Engl J Med. 2016 Mar 17;374(11):1093. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981943 No abstract available. - Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Rosenstein R, Hough A. Rosenstein R, et al. N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981944 No abstract available. - [Comment by Prof. Dr. med Dirk Müller-Wieland. The therapeutic goal for blood sugar lowering in diabetes treatment].
Müller-Wieland D. Müller-Wieland D. Med Monatsschr Pharm. 2016 Feb;39(2):63. Med Monatsschr Pharm. 2016. PMID: 26983334 German. No abstract available. - No Need to Sugarcoat the Message: Is Cardiovascular Risk Reduction From SGLT2 Inhibition Related to Natriuresis?
Perkins BA, Udell JA, Cherney DZ. Perkins BA, et al. Am J Kidney Dis. 2016 Sep;68(3):349-52. doi: 10.1053/j.ajkd.2016.03.410. Epub 2016 Mar 30. Am J Kidney Dis. 2016. PMID: 27039253 No abstract available. - Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes.
Guthrie R. Guthrie R. Postgrad Med. 2016 May;128(4):335-7. doi: 10.1080/00325481.2016.1174566. Epub 2016 Apr 18. Postgrad Med. 2016. PMID: 27043258 - Empagliflozin's Fuel Hypothesis: Not so Soon.
Lopaschuk GD, Verma S. Lopaschuk GD, et al. Cell Metab. 2016 Aug 9;24(2):200-2. doi: 10.1016/j.cmet.2016.07.018. Cell Metab. 2016. PMID: 27508868 - Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness.
Khunti K, Kosiborod M. Khunti K, et al. Diabetes Obes Metab. 2018 Apr;20(4):763-765. doi: 10.1111/dom.13142. Epub 2017 Nov 22. Diabetes Obes Metab. 2018. PMID: 29077267 No abstract available.
Similar articles
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14. N Engl J Med. 2016. PMID: 27299675 Clinical Trial. - Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
McGuire DK, Zinman B, Inzucchi SE, Wanner C, Fitchett D, Anker SD, Pocock S, Kaspers S, George JT, von Eynatten M, Johansen OE, Jamal W, Mattheus M, Elsasser U, Hantel S, Lund SS. McGuire DK, et al. Lancet Diabetes Endocrinol. 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2. Lancet Diabetes Endocrinol. 2020. PMID: 33217335 Clinical Trial. - Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13. Circulation. 2018. PMID: 28904068 Clinical Trial. - Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ. Levine MJ. Curr Diabetes Rev. 2017;13(4):405-423. doi: 10.2174/1573399812666160613113556. Curr Diabetes Rev. 2017. PMID: 27296042 Free PMC article. Review. - Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
Luconi M, Raimondi L, Di Franco A, Mannucci E. Luconi M, et al. Nutr Metab Cardiovasc Dis. 2016 Dec;26(12):1071-1078. doi: 10.1016/j.numecd.2016.09.001. Epub 2016 Sep 10. Nutr Metab Cardiovasc Dis. 2016. PMID: 27776917 Review.
Cited by
- How to utilize current guidelines to manage patients with cancer at high risk for heart failure.
Bloom M, Alvarez-Cardona JA, Ganatra S, Barac A, Pusic I, Lenihan D, Dent S. Bloom M, et al. Cardiooncology. 2024 Sep 28;10(1):63. doi: 10.1186/s40959-024-00259-5. Cardiooncology. 2024. PMID: 39342407 Free PMC article. Review. - Acute effects of empagliflozin on open-loop baroreflex function and urine output in streptozotocin-induced type 1 diabetic rats.
Kawada T, Yamamoto H, Fukumitsu M, Nishikawa T, Matsushita H, Yoshida Y, Sato K, Morita H, Alexander J Jr, Saku K. Kawada T, et al. J Physiol Sci. 2024 Sep 28;74(1):48. doi: 10.1186/s12576-024-00938-z. J Physiol Sci. 2024. PMID: 39342112 Free PMC article. - Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation.
Luo Y, Ye T, Tian H, Song H, Kan C, Han F, Hou N, Sun X, Zhang J. Luo Y, et al. Lipids Health Dis. 2024 Sep 27;23(1):308. doi: 10.1186/s12944-024-02293-9. Lipids Health Dis. 2024. PMID: 39334359 - Lifestyle Habits and Risk of Cardiovascular Mortality in Menopausal Women with Cardiovascular Risk Factors: A Retrospective Cohort Study.
Lopez-Pineda A, Soriano-Maldonado C, Arrarte V, Sanchez-Ferrer F, Bertomeu-Gonzalez V, Ruiz-Nodar JM, Quesada JA, Cordero A. Lopez-Pineda A, et al. J Cardiovasc Dev Dis. 2024 Sep 16;11(9):287. doi: 10.3390/jcdd11090287. J Cardiovasc Dev Dis. 2024. PMID: 39330345 Free PMC article. - Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling.
Minciună IA, Tomoaia R, Mihăilă D, Cismaru G, Puiu M, Roșu R, Simu G, Frîngu F, Irimie DA, Caloian B, Zdrenghea D, Pop D. Minciună IA, et al. Curr Issues Mol Biol. 2024 Aug 31;46(9):9607-9623. doi: 10.3390/cimb46090571. Curr Issues Mol Biol. 2024. PMID: 39329923 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical